



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In patent application of: Klierwer, et al.

US National Serial No: 09/276,935

Filed: March 26, 1999

Title: AN ORPHAN NUCLEAR RECEPTOR

TECH CENTER 1600/2900

DEC 03 2007

RECEIVED

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. § 1.821-1.825

Commissioner for Patents
Washington, D.C. 20231

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821 (g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (c) and (e), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted

11/27/02
Date


Michael M. Conger
Attorney of Record, Reg. No. 43562

GlaxoSmithKline
Corporate Intellectual Property Dept.
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398